MEDI4893: Phase II started

AstraZeneca’s Medimmune LLC unit began the double-blind, placebo-controlled, dose-ranging European Phase II SAATELLITE trial to evaluate 2 single doses of IV MEDI4893 in about 462 patients. The trial ...